Member's Area - Login/Register

SARS-CoV-2 vaccines from A to Z: A Review of the current challenges

Paper Topic: 

Pages :
148 - 171

Corresponing Author: 
Ghada Abd-Elmonsef Mahmoud
Muhammad J. Albalaty, Hagar F. Forsan, Sohaila S. Awad, Nehal E. Elsadek, Gehan A. Abdel Rahman, Mona Shaban E. M. BadawyW, Eman K. M. Khalfallah, Eman Sayed El-Wakil, Lamiaa Ibrahim Ahmed, Zeinab I. Ali, Asmaa S. Nofal, Reem M. Elsapagh, Amira M. Gomaa, Fathia H.E Bougafa, Somaya Abdulbaset Mahmoud, Mariam A. Moustafa, Fatma M. Ali, Hanaa M. Barakat, Aya M. Kandeel, Aya A. El Sebaei, Ghada Abd-Elmonsef Mahmoud
Paper ID: 
Paper Status: 
Date Paper Accepted: 
Paper online: 
Visual abstract: 

COVID-19 pandemic is a major worldwide health disaster firstly reported in December 2019. The Food and Drug Administration (FDA) has offered the public hope of halting it, authorizing vaccinations for emergency use with more than 85% efficacy against serious acute respiratory syndrome (SARS-CoV-2). Recent outbreaks of SARS-CoV-2 variations including spike-protein mutations, the key vaccines viral target for immune response, have prompted a thorough investigation into the vaccine's long-term effectiveness. Consequently, this review assayed the details on SARS-CoV-2 infection mechanism and how to control the infection by different types of SARS-CoV-2 vaccines, and their effectiveness against other mutant strains. Additionally, the review summarized the different complaints which have been recorded after vaccination. In conclusion, these negative effects must be constantly weighed against the predicted advantages in terms of disease prevention. Although COVID-19 vaccination is recommended for everyone aged 5 years and older, SARS-CoV-2 is high likely to continue to be a pandemic infectious as a result of the broadcasting of variants of the virus. Therefore, a booster vaccination, wearing a mask, and social distancing should be maintained.

SARS-CoV-2 vaccines, COVID-19, Neutralizing antibodies, Lambada mutation, Delta mutation, Mutant Omicron.